Medicover Polska is testing the ColonFlag modern solution that will allow to effectively identify patients at risk for colorectal cancer. The tool determines the risk of intestinal lesions by further analysing the results of a commonly performed blood test. The pilot project is being developed in collaboration with Medial EarlySign, an Israeli company that creates machine-learning systems in the area of data-driven medicine.
ColonFlag helps make diagnostic decisions thanks to applying advanced AI algorithms to data from frequently performed laboratory tests. The programme analyses data such as the results of a CBC test and other data contained in electronic medical records.
- Dr Piotr Soszyński, Director of Medical Systems at Medicover Polska
Colon cancer is the second most common cancer in women in Poland and the third among males. It is the fourth most common cause of death due to cancer. In Poland, the average survival rate after five years is slightly below 50%. If colorectal cancer is diagnosed at an early stage, the rate may even exceed 90%. Early detection has enormous importance for the successful treatment of colorectal cancer. ColonFlag can help us better identify patients in the high risk group. Thanks to this, referrals for colonoscopy may result in a better chance of detecting the disease and significantly improve the outcome of treatment.
- Dr Bożena Walewska-Zielecka, Medical Director at Medicover Polska
The success of the project may mean that Medicover Polska will begin using the ColonFlag tool in routine diagnostic procedures.
Specjalista ds. Komunikacji i PR at Healthcare Services, Medicover
Dyrektor ds. Komunikacji i Marki Korporacyjnej at Healthcare Services, Medicover